-+ 0.00%
-+ 0.00%
-+ 0.00%

Biopharmaceutical Company UCB Books Higher H1 Profit, Revenue

MT Newswires·07/30/2026 01:24:56
Listen to the news
01:24 AM EDT, 07/30/2026 (MT Newswires) -- UCB (UCB.BR) reported on Thursday that its attributable profit and revenue in the first half increased year over year. Profit attributable to equity holders for the six months ended June 30 was 1.11 billion euros, compared with 475 million euros earlier. EPS moved to 5.73 euros from 2.44 euros. The biopharmaceutical company's revenue was 4.27 billion euros, compared with 3.49 billion euros a year ago. For full-year 2026, the company expects revenue growth in the low-teens to mid-teens percentage range at constant exchange rates.